In obese prostate cancer patients, robotic surgery reduces risk of blood loss

May 20, 2016

MAYWOOD, IL. -- In obese prostate cancer patients, robotic-assisted surgery to remove the prostate reduces the risk of blood loss and prolonged hospital stays, a Loyola Medicine study has found.

The study by senior author Gopal Gupta, MD and colleagues is published in the journal Current Urology. Dr. Gupta is an assistant professor in the Department of Urology of Loyola University Chicago Stritch School of Medicine.

Researchers examined records of 9,108 obese men who underwent radical prostatectomy (removal of the prostate gland and some surrounding tissue). Among all patients, 60.4 percent underwent robotic-assisted radical prostatectomy and 39.6 percent underwent open prostatectomy.

Compared with patients who had open surgery, patients undergoing robotic-assisted surgery were 83 percent less likely to require blood transfusions and 72 percent less likely to require prolonged hospital stays. But robotic-assisted surgery did not reduce the risk of infections and other complications, the study found.

The robotic system allows surgeons to operate through a few small incisions. Movements by the surgeon's hand or wrist are translated into highly precise movements of the surgical instruments. Every maneuver is directed by the surgeon, in real time, as the surgeon views a magnified, 3D, high-definition image of the surgical site.

Prostate cancer is the most common solid organ cancer in men in the United States. One in six men will develop prostate cancer over their lifetimes, and many will choose to have radical prostatectomies. In the past decade, the use of robotic-assisted radical prostatectomy has surpassed that of open surgery.

More than one-third of adults in the United States are obese. Obese patients can be challenging, because many have related conditions such as diabetes, heart disease and obstructive sleep apnea that can increase the risk of blood transfusions, complications and prolonged length of stay.

Researchers concluded the study results have these implications: In the study, researchers examined records from the 2009-2010 Nationwide Impatient Sample maintained by the Agency for Healthcare Research and Quality.

Dr. Gupta's co-authors are Chandy Ellimoottil, MD, (first author), Robert Blackwell, MD, Adam Kadlec, MD, Kristin Greco, MD, and Marcus L. Quek, MD, all of Loyola; and Florian Roghmann, MD, Maxine Sun, MD and Quoc-Dien Trinh, MD, of the University of Montreal Health Center.

The study is titled, "Open Versus Robotic Radical Prostatectomy in Obese Men."
-end-


Loyola University Health System

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.